Go Pro
→ The cat is out the bag (From Porter & Company) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$223.95
+1.2%		$275.88
$197.81
▼
$495.55
$29.60B0.32.22 million shs1.62 million shs
Biogen Inc. stock logo
BIIB
Biogen
$208.87
+2.4%		$203.19
$129.40
▼
$219.72
$30.13B0.171.13 million shs788,945 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.74
+1.8%		$7.68
$1.95
▼
$12.43
$8.05B0.039.10 million shs5.33 million shs
Insmed, Inc. stock logo
INSM
Insmed
$132.28
-0.2%		$106.86
$90.39
▼
$212.75
$28.95B0.813.26 million shs1.56 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+1.94%+1.01%-25.96%-24.11%-49.15%
Biogen Inc. stock logo
BIIB
Biogen
-1.56%-2.19%+2.38%-0.31%+59.29%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+1.47%+9.35%-7.54%-6.75%+207.69%
Insmed, Inc. stock logo
INSM
Insmed
-1.62%+34.25%+14.67%+12.36%+17.43%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$223.95
+1.2%		$275.88
$197.81
▼
$495.55
$29.60B0.32.22 million shs1.62 million shs
Biogen Inc. stock logo
BIIB
Biogen
$208.87
+2.4%		$203.19
$129.40
▼
$219.72
$30.13B0.171.13 million shs788,945 shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$7.74
+1.8%		$7.68
$1.95
▼
$12.43
$8.05B0.039.10 million shs5.33 million shs
Insmed, Inc. stock logo
INSM
Insmed
$132.28
-0.2%		$106.86
$90.39
▼
$212.75
$28.95B0.813.26 million shs1.56 million shs
7 Stocks to Buy Before the Robotics Revolution Cover
7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
+1.94%+1.01%-25.96%-24.11%-49.15%
Biogen Inc. stock logo
BIIB
Biogen
-1.56%-2.19%+2.38%-0.31%+59.29%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
+1.47%+9.35%-7.54%-6.75%+207.69%
Insmed, Inc. stock logo
INSM
Insmed
-1.62%+34.25%+14.67%+12.36%+17.43%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2.92
Moderate Buy$396.7277.15% Upside
Biogen Inc. stock logo
BIIB
Biogen
2.56
Moderate Buy$224.617.53% Upside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$14.2083.46% Upside
Insmed, Inc. stock logo
INSM
Insmed
3.00
Buy$205.5255.37% Upside

Current Analyst Ratings Breakdown

Latest IBRX, BIIB, ALNY, and INSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/10/2026
Insmed, Inc. stock logo
INSM
Insmed
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$185.00 ➝ $195.00
8/10/2026
Insmed, Inc. stock logo
INSM
Insmed
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
8/10/2026
Insmed, Inc. stock logo
INSM
Insmed
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$179.00 ➝ $175.00
8/7/2026
Insmed, Inc. stock logo
INSM
Insmed
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$218.00
8/7/2026
Insmed, Inc. stock logo
INSM
Insmed
Evercore Inc logo
Evercore
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform$170.00
8/7/2026
Insmed, Inc. stock logo
INSM
Insmed
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$207.00 ➝ $205.00
8/7/2026
Insmed, Inc. stock logo
INSM
Insmed
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$172.00
8/7/2026
Insmed, Inc. stock logo
INSM
Insmed
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$161.00 ➝ $169.00
8/6/2026
Insmed, Inc. stock logo
INSM
Insmed
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$175.00
8/4/2026
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
Truist Financial Corporation logo
Truist Financial
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetBuy$410.00 ➝ $315.00
8/4/2026
Biogen Inc. stock logo
BIIB
Biogen
Mizuho logo
Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOutperform$221.00 ➝ $241.00
(Data available from 8/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$3.71B8.07$2.83 per share79.11$10.12 per share22.13
Biogen Inc. stock logo
BIIB
Biogen
$9.89B3.12$23.18 per share9.01$127.56 per share1.64
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M72.41N/AN/A($0.99) per share-7.82
Insmed, Inc. stock logo
INSM
Insmed
$606.42M47.64N/AN/A$3.47 per share38.12
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
$313.75M$5.3841.6323.21N/A15.26%84.93%14.30%10/29/2026 (Estimated)
Biogen Inc. stock logo
BIIB
Biogen
$1.29B$5.6536.9712.746.308.32%11.18%6.88%10/29/2026 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.97N/AN/AN/A-598.55%N/A-51.65%N/A
Insmed, Inc. stock logo
INSM
Insmed
-$1.28B-$4.11N/A53.34N/A-76.94%-123.94%-44.30%10/29/2026 (Estimated)

Latest IBRX, BIIB, ALNY, and INSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Insmed, Inc. stock logo
INSM
Insmed
-$0.6724-$0.06+$0.6124-$0.06$395.50 million$425.49 million
8/4/2026Q2 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.22-$0.14-$0.22$49.70 million$51.24 million
7/29/2026Q2 2026
Biogen Inc. stock logo
BIIB
Biogen
$2.94$3.60+$0.66$0.66$2.46 billion$2.74 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
N/AN/AN/AN/AN/A
Biogen Inc. stock logo
BIIB
Biogen
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
Insmed, Inc. stock logo
INSM
Insmed
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.75
3.05
2.99
Biogen Inc. stock logo
BIIB
Biogen
0.39
1.87
1.26
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
5.72
5.70
Insmed, Inc. stock logo
INSM
Insmed
0.74
3.72
3.40

Institutional Ownership

CompanyInstitutional Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
92.97%
Biogen Inc. stock logo
BIIB
Biogen
87.93%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%
Insmed, Inc. stock logo
INSM
Insmed
N/A

Insider Ownership

CompanyInsider Ownership
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
0.86%
Biogen Inc. stock logo
BIIB
Biogen
0.25%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
66.10%
Insmed, Inc. stock logo
INSM
Insmed
2.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alnylam Pharmaceuticals, Inc. stock logo
ALNY
Alnylam Pharmaceuticals
2,770133.81 million132.66 millionOptionable
Biogen Inc. stock logo
BIIB
Biogen
7,500147.75 million147.39 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
5901.06 billion359.28 millionOptionable
Insmed, Inc. stock logo
INSM
Insmed
1,664218.38 million213.80 millionOptionable

Recent News About These Companies

Insmed (NASDAQ:INSM) COO Sells 239,850 Shares
 |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insmed-nasdaqinsm-coo-sells-239850-shares-2026-08-12/
Insmed partners patient group on bronchiectasis study
 |  pharmaphorum.comP
HC Wainwright Brokers Increase Earnings Estimates for Insmed
August 12 at 6:26 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-brokers-increase-earnings-estimates-for-insmed-2026-08-12/
JPMorgan Chase & Co. Has Lowered Expectations for Insmed (NASDAQ:INSM) Stock Price
August 12 at 1:06 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30955121
Insmed (NASDAQ:INSM) Price Target Cut to $175.00 by Analysts at JPMorgan Chase & Co.
August 10 at 3:17 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insmed-nasdaqinsm-price-target-cut-to-17500-by-analysts-at-jpmorgan-chase-co-2026-08-10/
Pacer Advisors Inc. Has $1.19 Million Holdings in Insmed, Inc. $INSM
August 10 at 5:03 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-pacer-advisors-inc-has-119-million-holdings-in-insmed-inc-insm-2026-08-10/
Assenagon Asset Management S.A. Acquires 155,011 Shares of Insmed, Inc. $INSM
August 10 at 3:11 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-assenagon-asset-management-sa-acquires-155011-shares-of-insmed-inc-insm-2026-08-10/
Insmed (NASDAQ:INSM) Posts Earnings Results
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insmed-nasdaqinsm-posts-earnings-results-2026-08-08/
Insmed Shares Rise After Raising FY26 Guidance for Products
August 8, 2026  |  marketwatch.comhttps://www.marketwatch.com/story/insmed-shares-rise-after-raising-fy26-guidance-for-products-6a4771d6
Traders Purchase High Volume of Call Options on Insmed (NASDAQ:INSM)
August 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947626
Insmed (NASDAQ:INSM) Shares Gap Up on Earnings Beat
August 8, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30947279
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971081/insmed-tops-q2-earnings-estimates-stock-soars-34-on-brinsupri-uptake?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2971081
Quantinno Capital Management LP Grows Stock Holdings in Insmed, Inc. $INSM
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-quantinno-capital-management-lp-grows-stock-holdings-in-insmed-inc-insm-2026-08-07/
Insmed catapults 34%, leading a biotech rally but Mirum takes a bath
August 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/insmed-catapults-34-leading-a-biotech-rally-but-mirum-takes-a-bath/ar-AA29xGH6
Insmed catapults 30%, leading a biotech rally; but Mirum takes a bath
August 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/insmed-catapults-30-leading-a-biotech-rally-but-mirum-takes-a-bath/ar-AA29xGH6
Insmed raises BRINSUPRI revenue guidance after strong Q2 growth and expands peak sales outlook
August 6, 2026  |  msn.comhttps://www.msn.com/en-us/money/other/insmed-raises-brinsupri-revenue-guidance-after-strong-q2-growth-and-expands-peak-sales-outlook/ar-AA29xuK4
Insmed Q2 Earnings Call Highlights
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insmed-q2-earnings-call-highlights-2026-08-06/
Insmed Sees Unusually Large Options Volume (NASDAQ:INSM)
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insmed-sees-unusually-large-options-volume-nasdaqinsm-2026-08-06/
Insmed (INSM) Reports Q2 Earnings: What Key Metrics Have to Say
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2969755/insmed-insm-reports-q2-earnings-what-key-metrics-have-to-say?cid=cs-stocknewsapi-ft-fundamental_analysis|nfm-2969755
Insmed (NASDAQ:INSM) Shares Gap Up After Better-Than-Expected Earnings
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insmed-nasdaqinsm-shares-gap-up-after-better-than-expected-earnings-2026-08-06/
Insmed: Q2 Earnings Snapshot
August 6, 2026  |  chron.comhttps://www.chron.com/business/article/insmed-q2-earnings-snapshot-22376886.php

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alnylam Pharmaceuticals stock logo

Alnylam Pharmaceuticals NASDAQ:ALNY

$223.95 +2.75 (+1.24%)
As of 04:00 PM Eastern

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Biogen stock logo

Biogen NASDAQ:BIIB

$208.87 +4.98 (+2.44%)
As of 04:00 PM Eastern

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$7.74 +0.14 (+1.84%)
As of 04:00 PM Eastern

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Insmed stock logo

Insmed NASDAQ:INSM

$132.28 -0.29 (-0.22%)
As of 04:00 PM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas